Robert Gross

Author PubWeight™ 110.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012 7.04
2 Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010 5.64
3 Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 2008 4.20
4 Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007 3.75
5 The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009 3.67
6 HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007 3.05
7 A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 2004 2.97
8 Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008 2.82
9 Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis 2014 2.65
10 Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006 2.57
11 A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005 2.15
12 The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007 1.79
13 Racial disparities in hypertension control, but not treatment intensification. Am J Hypertens 2009 1.59
14 HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets 2011 1.53
15 Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep 2007 1.53
16 Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 2006 1.51
17 Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS 2012 1.42
18 Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004 1.41
19 Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 2008 1.36
20 Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010 1.36
21 Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007 1.35
22 Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr 2012 1.27
23 HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr 2007 1.26
24 Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J Pain Symptom Manage 2011 1.23
25 Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV-infected individuals. AIDS Behav 2007 1.22
26 Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007 1.17
27 Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011 1.17
28 Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf 2008 1.15
29 Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003 1.14
30 MACH14: a multi-site collaboration on ART adherence among 14 institutions. AIDS Behav 2013 1.14
31 Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA 2013 1.09
32 Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010 1.07
33 Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009 1.06
34 Endothelial cell density to predict endothelial graft failure after penetrating keratoplasty. Arch Ophthalmol 2010 1.05
35 Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008 1.04
36 Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2010 1.04
37 Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr 2013 1.03
38 Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. AIDS Behav 2008 1.01
39 Membrane-based, sedimentation-assisted plasma separator for point-of-care applications. Anal Chem 2013 1.01
40 Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. J Infect Dis 2013 1.00
41 Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 2013 0.96
42 Provider guidance for linking patients to antiretroviral therapy adherence interventions: recommendations from an IAPAC advisory committee on adherence monitoring and support. J Int Assoc Provid AIDS Care 2013 0.96
43 The validity of self-reported medication adherence as an outcome in clinical trials of adherence-promotion interventions: Findings from the MACH14 study. AIDS Behav 2014 0.95
44 Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav 2011 0.94
45 Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana. PLoS One 2011 0.94
46 Outcomes of HIV-infected patients receiving care at multiple clinics. AIDS Behav 2014 0.93
47 Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest 2009 0.93
48 HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol 2006 0.92
49 Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med 2010 0.90
50 Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported. Pharmacoepidemiol Drug Saf 2005 0.89
51 Rapid psychosocial function screening test identified treatment failure in HIV+ African youth. AIDS Care 2012 0.89
52 A randomized trial of a nursing intervention for HIV disease management among persons with serious mental illness. Psychiatr Serv 2011 0.88
53 Is antiretroviral therapy adherence substantially worse on weekends than weekdays? J Acquir Immune Defic Syndr 2010 0.88
54 Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression. J Infect Dis 2003 0.87
55 Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 2007 0.87
56 Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc 2010 0.87
57 Effect of GB virus C viremia on HIV acquisition and HIV set-point. AIDS 2005 0.87
58 The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. Basic Clin Pharmacol Toxicol 2005 0.87
59 Risk factors for suboptimal antiretroviral therapy adherence in HIV-infected adolescents in Gaborone, Botswana: a pilot cross-sectional study. Patient Prefer Adherence 2013 0.87
60 Vitamin D status in HIV-infected patients with and without tuberculosis: a pilot study. J Acquir Immune Defic Syndr 2012 0.86
61 How long is the right interval for assessing antiretroviral pharmacy refill adherence? J Acquir Immune Defic Syndr 2010 0.84
62 Validation of the Pediatric Symptom Checklist in HIV-infected Batswana. J Child Adolesc Ment Health 2011 0.84
63 Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model. AIDS Care 2015 0.84
64 Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline. Int J Neurosci 2015 0.82
65 Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr 2015 0.82
66 Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. J Clin Epidemiol 2006 0.81
67 Acceptance of hepatitis B vaccination by pregnant adolescents. MCN Am J Matern Child Nurs 2005 0.81
68 Evaluating the President's Emergency Plan for AIDS Relief: time to scale it up. Ann Intern Med 2009 0.81
69 The association between poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and implications for scale-up of treatment as prevention. AIDS Behav 2014 0.81
70 A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma. PLoS One 2013 0.81
71 Application of high-frequency Granger causality to analysis of epileptic seizures and surgical decision making. Epilepsia 2014 0.81
72 Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 2013 0.80
73 Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol 2008 0.80
74 Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS 2012 0.79
75 Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDS 2004 0.78
76 Sickle cell patient with an acute chest syndrome and a negative chest X-ray: potential role of the ventilation and perfusion (V/Q) lung scan. Am J Hematol 2003 0.77
77 Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One 2011 0.77
78 Factors associated with a willingness to accept rapid HIV testing in an urban emergency department. AIDS Behav 2014 0.77
79 Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med 2008 0.76
80 Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences. Pharmacoepidemiol Drug Saf 2014 0.76
81 Health Outcomes of HIV-Infected People with Mental Illness. AIDS Behav 2015 0.75
82 Research letter: Do physicians discuss political issues with their patients? J Gen Intern Med 2006 0.75
83 Toward improved adverse event/suspected adverse drug reaction reporting. Pharmacoepidemiol Drug Saf 2003 0.75
84 CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-treated HIV-Infected Patients in Botswana. J Acquir Immune Defic Syndr 2017 0.75